Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.
With the iSPERSE platform, the company has demonstrated comprehensive data showing that iSPERSE can be applied to a broad range of therapeutic compounds ranging from small molecules including our novel iCALM (inhaled Cationic Airway Lining Modulator) therapies through proteins and antibodies. Potential advantages of iSPERSE platform therapeutics on clinical treatment efficacy include reduced total inhaled powder mass, enhanced dosing efficiency, reduced cost of goods and improved safety and tolerability profiles. Further optimization of select iSPERSE therapeutic formulations across a range of drug loads has yielded promising results on stability testing, process engineering, manufacturing, and scale up, demonstrating the potential of the platform as a next generation engineered particle technology.
The iSPERSE pipeline is targeted at prevention and treatment of a range of respiratory diseases with significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and bronchiectasis. The company’s lead host-targeted iCALM drug candidate (PUR118), based on the iSPERSE platform is in clinical testing as an anti-inflammatory for COPD and CF. A second clinical stage iSPERSE candidate (PUR0200) is a long acting bronchodilator and will start clinical trials in COPD in 2013. Additional iSPERSE pipeline targets including a novel bronchodilator for COPD, a novel antimicrobial for CF, inhaled antibiotics for CF and bronchiectasis, and a novel inhaled biologic for IPF, are in preclinical development.